OncBioMune reports additional Phase I data for prostate cancer vaccine

OncBioMune Pharmaceuticals Inc. (OTCQB:OBMP) reported additional data from 14 evaluable patients with hormone-naïve and hormone-independent recurrent prostate cancer

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE